## Aftin-4

Cat. No.:	HY-111267		
CAS No.:	866893-90-5		
Molecular Formula:	C <sub>20</sub> H <sub>28</sub> N <sub>6</sub> O		
Molecular Weight:	368.48		
Target:	Amyloid-β		
Pathway:	Neuronal Signaling		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year

MedChemExpress

## SOLVENT & SOLUBILITY

In Vitro	DMSO : ≥ 100 mg/mL (271.39 mM) * "≥" means soluble, but saturation unknown.					
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg	
		1 mM	2.7139 mL	13.5693 mL	27.1385 mL	
		5 mM	0.5428 mL	2.7139 mL	5.4277 mL	
		10 mM	0.2714 mL	1.3569 mL	2.7139 mL	
	Please refer to the so	lubility information to select the app	propriate solvent.			
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (6.78 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (6.78 mM); Clear solution					
	3. Add each solvent of Solubility: ≥ 2.5 m	one by one: 10% DMSO >> 90% con g/mL (6.78 mM); Clear solution	n oil			

## BIOLOGICAL ACTIVITY Description Aftin-4 is an Amyloid-β<sub>42</sub> (Aβ<sub>42</sub>) inducer. IC<sub>50</sub> & Target Amyloid-β<sup>[1]</sup>. In Vitro Aftin-4 selectively and potently increases Aβ<sub>1-42</sub> in N2a cells, primary neurons, and brain lysates, with an EC<sub>50</sub> value around 30 μM<sup>[1]</sup>.

	MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Aftin-4 increases $A\beta_{1-42}$ levels in vivo in mice and provokes rapidly a sustained toxicity highly reminiscent of Alzheimer's disease (AD). Aftin-4 is administered at increasing doses, between 3 and 20 nmol/mouse, into the lateral ventricle and animals are sacrificed at various time points, between 3 to 14 days after injection. The hippocampus is dissected out the contents in $A\beta_{1-42}$ or $A\beta_{1-42}$ is determined using a mouse ELISA assay. Aftin-4 dose-dependently and significantly increases A $\beta_{1-42}$ content, up to +216% at the highest dose tested <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL	
TROTOCOL	
Animal Administration <sup>[1]</sup>	<ul> <li>Mice<sup>[1]</sup></li> <li>Male Swiss OF-1 mice, aged 7-9 weeks and weighing 32±2 g are used. Aftin-4 is solubilized in DMSO at a concentration of 3 mg/mL and stored at -20°C until use. Aftin-4 is administered intracerebroventricularly (i.c.v.), with a Hamilton microsyringe equipped with a 3-mm needle in a final volume of 3 μL per mouse. The injection coordinates are -0.4 mm with respect to bregma, 1.00mm to the right from the central, and 2.50mm in depth. Aftin-4 is also injected intraperitoneally (i.p.). Aftin-4 is solubilized in DMSO 40% in distilled water at 2, 6 or 20 mg/mL and administered in a final volume of 100 μL/20 g body weight <sup>[1]</sup>.</li> <li>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</li> </ul>

## REFERENCES

[1]. Meunier J, et al. Brain toxicity and inflammation induced in vivo in mice by the amyloid-β forty-two inducer aftin-4, a roscovitine derivative. J Alzheimers Dis. 2015;44(2):507-24.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA